Edwards Lifesciences Corp (EW) Q4 2021 (USD): Adj. EPS 0.51 (exp. 0.55), Revenue 1.33bln (exp. 1.35bln).
- FY22 guidance unchanged.
- Q1 total sales view between 1.27-1.35bln.
- Q1 adj. EPS of 0.54-0.62.
- Believe that opportunity to serve patients will nearly double between now and 2028.
Via PR Newswire
26 Jan 2022 - 21:15- - Source: PR Newswire
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts